Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe Française De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML

Blood (2010) 116 (21): 2266.

https://doi.org/10.1182/blood.V116.21.2266.2266

Published: 2010

Journal Articles

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Catherine Roche-Lestienne, Marceau Alice, Elise Labis, Olivier Nibourel, Valérie Coiteux, Joelle Guilhot, Laurence Legros, MD, Franck Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Martine Gardembas, Nathalie Helevaut, Cécile Frimat, Francois Guilhot, Claude Preudhomme

Blood (2010) 116 (21): 3377.

https://doi.org/10.1182/blood.V116.21.3377.3377

Published: 2010

Journal Articles

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD, Sandrine Hayette, PhD

Blood (2008) 112 (11): 1103.

https://doi.org/10.1182/blood.V112.11.1103.1103

Published: 2008

Journal Articles

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Xiaoyan Jiang, MD, PhD, Donna Forrest, MD, Franck Nicolini, MD, PhD, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Clayton Smith, MD, Allen Eaves, MD, PhD, Connie Eaves, PhD

Blood (2007) 110 (11): 324.

https://doi.org/10.1182/blood.V110.11.324.324

Published: 2007

Journal Articles

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Catherine Roche-Lestienne, PhD, Laureline Deluche, MD, Selim Corm, MD, Isabelle Tigaud, MD, Sami Joha, PhD, Nathalie Philippe, PhD, Sandrine Geffroy, PhD, Jean-Luc Lai, PhD, Franck Nicolini, MD, PhD, Claude Preudhomme, MD, PhD

Blood (2007) 110 (11): 2786.

https://doi.org/10.1182/blood.V110.11.2786.2786

Published: 2007

Journal Articles

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Francois-Xavier Mahon, MD, PhD, Stéphane Picard, MD, Karine Titier, MD, Franck Nicolini, MD, PhD, Dominique Ducint, MD, Nicolas Moore, MD, PhD, Gerald Marit, MD, Patrice Berthaud, MD, Mathieu Molimard, MD, PhD

Blood (2005) 106 (11): 1995.

https://doi.org/10.1182/blood.V106.11.1995.1995

Published: 2005

Journal Articles

B-Cell Depletion and Prevention of Hemolysis in Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO Incompatibility.

Emmanuelle Tavernier, MD, Anne Thiebaut, MD, Franck Nicolini, MD, PhD, Quoc Hung Le, MD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Daniela Revesz, MD, Olivier Hecquet, MD, PhD, Philippe Dubost, Jean-Paul Bourgeot, Mauricette Michallet, MD, PhD

Blood (2004) 104 (11): 5151.

https://doi.org/10.1182/blood.V104.11.5151.5151

Published: 2004

NARROW

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

B-Cell Depletion and Prevention of Hemolysis in Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO Incompatibility.

Email alerts

ASH Publications

American Society of Hematology

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

B-Cell Depletion and Prevention of Hemolysis in Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO Incompatibility.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only